And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

Thomas John Dietz net worth and biography

Thomas Dietz Biography and Net Worth

Director of Eiger BioPharmaceuticals

Dr. Thomas J. Dietz Ph.D. serves as Independent Chairman of the Board of the Company. He has been a member of Private Eiger’s board of directors since his appointment in October 2015 and assumed the same position at the Company in March 2016. Dr. Dietz has served as Chairman and CEO of Waypoint Holdings, LLC, a financial services firm, since December 2010. Dr. Dietz was previously co-CEO and then CEO and a director of Pacific Growth Equities, LLC, an investment bank and institutional brokerage firm, from 2004 to January 2009, when the firm was acquired by Wedbush Securities, a financial services firm. Dr. Dietz subsequently served as head of the investment banking division at Wedbush until November 2010. Dr. Dietz joined Pacific Growth in 1993 and served in various roles, including senior roles in equities research and investment banking, prior to taking the CEO role there. Previously, Dr. Dietz was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University in St. Louis. Dietz’s qualifications to sit on the board of directors include his medical and research background and extensive finance and executive experience in the financial services industry.

What is Thomas John Dietz's net worth?: The estimated net worth of Thomas John Dietz is at least $0.00 as of January 23rd, 2023. Mr. Dietz owns 1,666 shares of Eiger BioPharmaceuticals stock worth more than $0 as of April 25th. This net worth approximation does not reflect any other assets that Mr. Dietz may own. Learn More about Thomas John Dietz's net worth.
How do I contact Thomas John Dietz?: The corporate mailing address for Mr. Dietz and other Eiger BioPharmaceuticals executives is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. Eiger BioPharmaceuticals can also be reached via phone at (650) 272-6138 and via email at [email protected]. Learn More on Thomas John Dietz's contact information.
Has Thomas John Dietz been buying or selling shares of Eiger BioPharmaceuticals?: Thomas John Dietz has not been actively trading shares of Eiger BioPharmaceuticals in the last ninety days. Most recently, on Monday, January 23rd, Thomas John Dietz bought 1,666 shares of Eiger BioPharmaceuticals stock. The stock was acquired at an average cost of $42.90 per share, with a total value of $71,471.40. Following the completion of the transaction, the director now directly owns 1,666 shares of the company's stock, valued at $71,471.40. Learn More on Thomas John Dietz's trading history.
Who are Eiger BioPharmaceuticals' active insiders?: Eiger BioPharmaceuticals' insider roster includes Thomas Dietz (Director), Evan Loh (Director), and Eldon Mayer, III (VP). Learn More on Eiger BioPharmaceuticals' active insiders.
Are insiders buying or selling shares of Eiger BioPharmaceuticals?: During the last twelve months, Eiger BioPharmaceuticals insiders bought shares 2 times. They purchased a total of 5,940 shares worth more than $44,170.20. The most recent insider tranaction occured on November, 2nd when Major Shareholder Richard A Kayne bought 779 shares worth more than $7,011.00. Insiders at Eiger BioPharmaceuticals own 4.2% of the company. Learn More about insider trades at Eiger BioPharmaceuticals.
Information on this page was last updated on 11/2/2023.

Thomas John Dietz Insider Trading History at Eiger BioPharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/23/2023	Buy	1,666	$42.90	$71,471.40	1,666
12/22/2022	Sell	750	$35.10	$26,325.00	700
4/9/2021	Buy	83	$254.70	$21,140.10	1,216
1/10/2020	Buy	133	$415.20	$55,221.60	800
4/22/2019	Buy	166	$331.50	$55,029.00	500
12/20/2018	Buy	166	$299.40	$49,700.40	333
12/6/2018	Buy	166	$337.80	$56,074.80	166

Thomas John Dietz Buying and Selling Activity at Eiger BioPharmaceuticals

Eiger BioPharmaceuticals Company Overview

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Today's Range

Now: N/A

50 Day Range

MA: $4.85

$1.30

$7.17

2 Week Range

Now: N/A

Volume

137,800 shs

Average Volume

103,866 shs

Market Capitalization

$2.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83

He Is Giving Away Bitcoin

From Crypto Swap Profits | Ad

>> Register right here